NDA for Additional Rheumatoid Arthritis Indication of Methotrexate Injection Approved in China
2024-08-05

NDA for Additional Rheumatoid Arthritis Indication of Methotrexate Injection Approved in China

Receiving “AA” once again in MSCI ESG Rating, being positioned at the industry leading level globally
2024-07-16

Receiving “AA” once again in MSCI ESG Rating, being positioned at the industry leading level globally

Included in S&P Global’s 2024 Sustainability Yearbook (China Edition)

Included in S&P Global’s 2024 Sustainability Yearbook (China Edition)

Innovative Drug Methylthioninium Chloride Enteric-coated Sustained-release Tablets (Lumeblue®) Approved for Marketing in China
2024-06-18

Innovative Drug Methylthioninium Chloride Enteric-coated Sustained-release Tablets (Lumeblue®) Approved for Marketing in China

Obtained Exclusive License of a Regenerative Collagen Light Medical Aesthetic Product Decellularized Extracellular Matrix Implant
2024-06-07

Obtained Exclusive License of a Regenerative Collagen Light Medical Aesthetic Product Decellularized Extracellular Matrix Implant

“Kangzhe” Brand was Awarded the 21st “Shenzhen Top Brand (Bay Area Top Brand)”
2024-05-10

“Kangzhe” Brand was Awarded the 21st “Shenzhen Top Brand (Bay Area Top Brand)”

New Drug Application of Desidustat Tablets Accepted in China
2024-04-23

New Drug Application of Desidustat Tablets Accepted in China

Pharmaceutical Administration Bureau (ISAF) of Macau has approved the new drug application of Ruxolitinib Cream
2024-04-16

Pharmaceutical Administration Bureau (ISAF) of Macau has approved the new drug application of Ruxolitinib Cream

CMS and Incyte Announce Collaboration and License Agreement for Povorcitinib, an Oral JAK1 Inhibitor, in mainland China, Hong Kong, Macau, Taiwan and Southeast Asia
2024-04-01

CMS and Incyte Announce Collaboration and License Agreement for Povorcitinib, an Oral JAK1 Inhibitor, in mainland China, Hong Kong, Macau, Taiwan and Southeast Asia

Approval to Conduct a Phase 3 Clinical Trial Investigating Ruxolitinib Cream in Atopic Dermatitis in China
2024-03-19

Approval to Conduct a Phase 3 Clinical Trial Investigating Ruxolitinib Cream in Atopic Dermatitis in China

As the First Prescription Issued, Innovative Drug Velphoro® has entered National Scale Clinical Application
2024-02-08

As the First Prescription Issued, Innovative Drug Velphoro® has entered National Scale Clinical Application

Two Innovative Drugs：Highly Selective TYK2 Inhibitor CMS-D001 and GnRH Receptor Antagonist CMS-D002 are approved for Drug Clinical Trials
2024-02-07

Two Innovative Drugs：Highly Selective TYK2 Inhibitor CMS-D001 and GnRH Receptor Antagonist CMS-D002 are approved for Drug Clinical Trials